De Marca

XARELTO RIVAROXABAN 20 MG 28 TABS

~~$ 3,643.00~~ $ 3,424.42

XATRAL OD (ALFUZOSINA) 10MG 28 TABLETAS

~~$ 3,295.00~~ $ 2,701.90

XINTILAN (SIMVASTATINA) 20MG 30TABLETAS

~~$ 370.44~~ $ 111.13

XUMER (ETORICOXIB) 90MG 14TAB

~~$ 1,222.58~~ $ 1,039.19

XYLOCAINA (LIDOCAINA) AL 2% 50 ML SOLUCIÓN INYECTABLE

$ 119.35

YASMIN (DROSPIRENONA - ETINILESTRADIOL) 3 MG/0.03 MG 21 TAB

$ 641.00

YASMIN (DROSPIRENONA / ETINILESTRADIOL)

Comparable a: Yasmin
Sustancia activa: Drospirenona / Etinilestradiol
Concentración: 3 mg / 0.03 mg por tableta
Presentación: Caja con 21 tabletas
Laboratorio: BAYER
Origen: México

Yasmin es un medicamento anticonceptivo oral combinado que se utiliza para prevenir el embarazo. La drospirenona y el etinilestradiol actúan de manera conjunta para inhibir la ovulación, alterar el moco cervical y modificar el endometrio, reduciendo así la probabilidad de una concepción.

El consumo de este producto es responsabilidad de quien lo recomienda y quien lo usa. Consulte a su médico antes de consumir cualquier medicamento.

THERAPEUTIC INDICATIONS:

Oral contraceptive with antiandrogenic effects antimineralocorticoid and also beneficial for women with fluid retention of hormone and the resulting symptoms and women with acne and seborrhea.

CONTRAINDICATIONS: Do not use oral contraceptives (COCs) in the presence of any of the situations listed below. Must cease immediately the use of prepared if any of them for the first time during his employment:

• Presence or history of thrombotic / thromboembolic arterial or venous (eg, deep vein thrombosis, pulmonary embolism, myocardial infarction) or stroke.

• Presence or history of prodrome of a thrombosis (eg transient ischemic attack, angina pectoris).

• History of migraine with focal neurological symptoms.

• Diabetes mellitus with vascular involvement.

• The presence of a serious risk factor or multiple risk factors for arterial or venous thrombosis may also constitute a contraindication (see Precautions).

• Presence or history of pancreatitis if it is associated with hypertriglyceridemia.

• Presence or history of severe liver disease while the liver function values have not returned to normal.

• severe renal insufficiency or acute renal failure.

• Presence or history of liver tumors (benign or malignant).

• known or suspected neoplasms, influenced by sex steroids (for example, of the genitals or the breasts).

• Undiagnosed vaginal bleeding.

• Pregnancy known or suspected.

• Hypersensitivity to the active substances or any of the excipients.

RESTRICTIONS OF USE DURING PREGNANCY AND LACTATION: YASMIN ® is not indicated during pregnancy. If a woman becomes pregnant while taking YASMIN ®, discontinue administration.

However, epidemiological studies on a large scale have not revealed an increased risk of birth defects in children of mothers who used COCs prior to pregnancy or a teratogenic effect when COCs were taken inadvertently during early pregnancy.

The available data on the use of Yasmin ® during pregnancy are too limited to draw conclusions about the negative effects of Yasmin ® about pregnancy, health of the fetus or the newborn. Not yet available relevant epidemiological data.

Breastfeeding can be affected by the AOC, as they may reduce the amount of milk and alter its composition and therefore should not be recommended in general the use of AOC until the mother has not completely stopped breastfeeding. Small amounts of contraceptive steroids and / or its metabolites can be eliminated by milk.
DOSAGE AND ADMINISTRATION:

How to take Yasmin ®: If taken properly, combined oral contraceptives have a failure rate of about 1% per year. This failure rate may increase if you forget or take the pill incorrectly. Thetablets should be taken in the order indicated on the package every day at about the same time with a little liquid if necessary. It will take one tablet daily for 21 consecutive days. Each package will start back after an interval of 7 days without pills, which usually occurs during a withdrawal bleed. The bleeding usually begin 2-3 days after taking the last tablet and may not have finished where appropriate to start the next pack.